Please assess the completion status of the following clinical trial:

Trial Title: A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects from 16 to 75 years, both inclusive~* Well-characterized focal epilepsy or epileptic syndrome~* Subjects having at least 2 but not exceeding 40 partial onset seizures, whether or not secondarily generalized per 4 weeks during the 8-week Baseline Period~* Subjects on a stable dose of at least 1 but no more than 2 concomitant Antiepileptic Drugs (AEDs) with the second AED ≤ 50 % of the minimum recommended maintenance dose~Exclusion Criteria:~* Seizure type IA non-motor as only seizure type~* History or presence of seizures occurring too frequently or indistinctly separated to be reliably counted during the 6 months preceding Visit 1 or during Baseline~* Other serious uncontrolled disease

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Brivaracetam 50 mg (Type: EXPERIMENTAL): 50 mg/day
- Brivaracetam 100 mg (Type: EXPERIMENTAL): 100 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).